CD46 is a cellular receptor for species D human adenovirus
Several human adenovirus species D (HAdV-D) types are currently used, or under development, as viral vectors for vaccines and gene delivery. However, the unusually broad tropism observed in many HAdV-D types limits their specificity and effectiveness as targeted vectors. Since tropism is largely governed by receptor usage, and previous studies have reported conflicting findings on receptor preferences within this species, clarifying receptor usage is essential. In this study, we systematically investigated receptor usage in 18 different HAdV-D types and identified CD46 as the primary receptor. Since CD46 is widely expressed across human tissues, our findings explain the broad cellular tropism of these viruses and provide valuable insight for the rational design and refinement of HAdV-D-based vectors.
Authors
- Niklas Arnberg (ORCID: https://orcid.org/0000-0002-7069-6678)
- Lars Frängsmyr (ORCID: https://orcid.org/0000-0002-6523-5156)
- Gabriel González (ORCID: https://orcid.org/0000-0002-2180-2120)
- Katarina Danskog (ORCID: https://orcid.org/0000-0003-0573-4719)
- Annasara Lenman (ORCID: https://orcid.org/0000-0001-5109-9408)
- F Petersen (ORCID: https://orcid.org/0000-0002-2636-0421)
- Miriam Becker (ORCID: https://orcid.org/0000-0002-3634-066X)
Institutions
- University of Veterinary Medicine Hannover, Foundation (DE)
- Hokkaido University (JP)
- Science for Life Laboratory (SE)
- Institut de Recherche Vaccinale (FR)
- Helmholtz Centre for Infection Research (DE)
- University of Veterinary Medicine (HU)
- Center for Experimental and Clinical Infection Research (DE)
- Umeå University (SE)
Publication Details
- Journal
- mBio
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1128/mbio.01587-25
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Vetenskapsrådet
- HORIZON EUROPE Framework Programme